INmune Bio to present Phase 2 imaging data for XPro at AAIC 2026
Tweet Send to a Friend
INmune Bio Inc. (NASDAQ: INMB) announced new imaging data from its Phase 2 study of XPro in patients with early ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
